Emerging formats for next-generation antibody drug conjugates

Expert Opinion on Drug Discovery

Volumn 10, Issue 5, 2015, Pages 463-481

  Deonarain, Mahendra P ^a,b,c   Yahioglu, Gokhan ^a,b   Stamati, Ioanna ^a,b   Marklew, Jared ^a  

^a Antikor Biopharma Ltd   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; Conjugate; Drug; Fab; Format; Fragment; Linker; Single chain Fv

Indexed keywords

AMINO ACID; ANTIBODY CONJUGATE; CYSTEINE; DRUG ANTIBODY; GLYCAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LYSINE; PROTEIN; THIOL; ANTIBODY;

ANTIBODY ENGINEERING; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; ENZYME MODIFICATION; HUMAN; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; PROTEIN ENGINEERING;

EID: 84928347144     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1025049     Document Type: Review

References (121)

1. Evans JB, Syed BA. Next generation antibodies. Nature Rev Drug Discov 2014;13:413-14
2. Zolot RS, Basu S, Million RP. Antibody drug conjugates. Nature Rev Drug Disc 2013;12:259-60
3. Rostami S, Qazi I, Sikorski R. The clinical landscape of antibody drug conjugates. ADC Review. Available from: http://adcreview.com/articles/doi-10-14229jadc-2014-8-1-001/[Accessed 17 January 2015]
4. Beck A, Reichert JM. Antibody drug conjugates. MABs 2014;6:15-17
5. Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 2014;53:3796-827
6. Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 2013;81:113-21
7. Okeley NM, Alley SC, Senter PD. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug. Hematol Oncol Clin North Am 2014;28:13-25
8. Goldmacher VS, Kovtun YV. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv 2011;2:397-416
9. Welslau M, Dieras V, Sohn JH, et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 2014;120:642-51
10. Garnock-Jones KP. Brentuximab vedotin: a review of its use in patients with non-hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs 2013;73:371-81
11. Litvak-Greenfeld D, Benhar I. Risks and untoward toxicities of antibody-based immunoconjugates. Adv Drug Deliv Rev 2012;64:1782-99
12. Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother 2013;62:217-23
13. Perez HL, Cardarelli PM, Deshpande S, et al. Antibody-drug conjugates: current status and future directions. Drug Discov Today 2014;19:869-81
14. Klinguer-Hamour C, Strop P, Shah DK, et al. World Antibody Drug Conjugate Summit. MAbs 2014;6:18-29
15. Ardel J, Faulstich H, Strout P, et al. Methods in molecular biology. In: Ducry L, editor. Antibody-Drug Conjugate Payloads' Antibody-Drug Conjugates. 1045 Humana Press, New York, USA; 2013. p. 51-70
16. Gerber HP, Koehn FE, Abraham RT. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 2013;30:625-39
17. Gromek SA, Balunas MJ. Natural products as exquisitely potent cytotoxic payloads for antibody-drug conjugates. Curr Top Med Chem 2014;14:2822-34
18. Lessons Learned from 30+ years of ADC Development. Immunogen presentation. World ADC Summit; San Diego: 2014
19. Govindan SV, Cardillo TM, Rossi EA, et al. Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug. Mol Pharm 2014. [Epub ahead of print]
20. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 2014;7:24
21. Strohl WR. Antibody discovery: sourcing of monoclonal antibody variable domains. Curr Drug Discov Technol 2014;11:3-19
22. Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006;12:1373-82
23. Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12:2591-6
24. Golfier S, Kopitz C, Kahnert A, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 2014;13:1537-48
25. Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1(T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56
26. McDonagh CF, Kim KM, Turcott E, et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther 2008;7:2913-23
27. Gillies SD, Wesolowski JS. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Hum Antibodies Hybridomas 1990;1:47-54
28. Almagro JC, Gilliland GL, Breden F, et al. Antibody engineering and therapeutics, the annual meeting of the antibody society. MAbs 2014;6:577-618
29. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87
30. Beckley NS, Lazzareschi KP, Chih HW, et al. Investigation into temperature-induced aggregation of an antibody drug conjugate. Bioconjug Chem 2013;24:1674-83
31. Guo J, Kumar S, Prashad A, et al. Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol-maleimide chemistry. Pharm Res 2014;31:1710-23
32. Lauer TM, Agrawal NJ, Chennamsetty N, et al. Developability index: a rapid in silico tool for the screening of antibody naggregation propensity. J Pharm Sci 2012;101:102-15
33. Harper J, Mao S, Strout P, et al. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization. Methods Mol Biol 2013;1045:41-9
34. Available from: http://www.moradec.com/catalog-adc.html [Accessed 17 January 2015]
35. Kellner C, Bleeker WK, Lammerts van Bueren JJ, et al. Human kappa light chain targeted Pseudomonas exotoxin A-identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development. J Immunol Methods 2011;371:122-33
36. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33
37. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31
38. Wakankar A, Chen Y, Gokarn Y, et al. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011;3:161-72
39. Moldenhauer G, Salnikov AV, Lüttgau S, et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 2012;104:622-34
40. Heidelberg Pharma patent. Amatoxin derivatives. WO135282; 2014
41. Gianolio DA, Rouleau C, Bauta WE, et al. Targeting HER2-positive cancer with dolastatin-15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Cancer Chemother Pharmacol 2012;70:439-49
42. Wang L, Amphlett G, Blättler WA, et al. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005;14:2436-46
43. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84
44. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity monomethylauristatin f through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity bioconjugate chem. 2006;17:114-24
45. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-70
46. Dokter W, Ubink R, van der Lee M, et al. Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther 2014;13:2618-29
47. Zhou Q, Stefano JE, Manning C, et al. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug Chem 2014;25:510-20
48. Li X, Fang T, Boons GJ. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem Int Ed Engl 2014;53:7179-82
49. Panowski S, Bhakta S, Raab H, et al. Site specific antibody drug conjugates for cancer therapy. MAbs 2014;6:34-45
50. Van Delft F. Synaffix presentation. World ADC Summit; San Diego: 2014
51. Sweeny L, Hartman YE, Zinn KR, et al. A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma. Oral Oncol 2013;49:991-7
52. Lowinger T. Mersana presentation. World ADC Summit; San Diego: 2014
53. Behrens CR, Liu B. Methods for site-specific drug conjugation to antibodies. MAbs 2014;6:46-53
54. MedImmune patent. Engineered Fc regions for site specific conjugation. US0213705; 2012
55. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves thetherapeutic index. Nat Biotechnol 2008;26:925-32
56. Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184-9
57. Jeffrey SC, Burke PJ, Lyon RP, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013;24:1256-63
58. Li X, Yang J, Rader C. Antibody conjugation via one and two C-terminal selenocysteines. Methods 2014;65:133-8
59. Rader C. Chemically programmed antibodies. Trends Biotechnol 2014;32:186-97
60. Hallam TJ, Smider VV. Unnatural amino acids in novel antibody conjugates. Future Med Chem 2014;6:1309-24
61. Zimmerman ES, Heibeck TH, Gill A, et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem 2014;25:351-61
62. Axup JY, Bajjuri KM, Ritland M, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci USA 2012;109:16101-6
63. Tian F, Lu Y, Manibusan A, et al. A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci USA 2014;111:1766-71
64. Zimmerman ES, Heibeck TH, Gill AG, et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem 2014;25:35-361
65. Xiao H, Chatterjee A, Choi SH, et al. Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells. Angew Chemie Int Ed 2013;52:14080-803
66. Strop P, Liu SH, Dorywalska M, et al. Location matters:site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 2013;20:161-7
67. Dennler P, Chiotellis A, Fischer E, et al. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem 2014;25:569-78
68. Agarwal P, van der Weijden J, Sletten EM, et al. Pictet-Spengler ligation for protein chemical modification. Proc Natl Acad Sci USA 2013;110:46-51
69. Agarwal P, Kudirka R, Albers AE, et al. Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconjug Chem 2013;24:846-51
70. Albers AER, Garofalo AW, Drake PM, et al. Exploring the effects of linker composition on site-specifically modified antibodyedrug conjugates. Eur J Med Chem 2014;88:3-9
71. Ban H, Nagano M, Gavrilyuk J, et al. Facile and stabile linkages through tyrosine: bioconjugation strategies with the tyrosine-click reaction. Bioconj. Chem 2013;24:520-32
72. Polu KR, Lowman HB. Probody therapeutics for targeting antibodies to diseased tissue Exp. Opin Bio Ther 2014;14:1049
73. Sagert J, West J, Wong C, et al. Transforming Notch ligands into tumorantigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2. Cancer Res 2014;74(19 Suppl):abstract 2665
74. Metz S, Haas AK, Daub K, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci USA 2011;108:8194-9
75. Govindan SV, Cardillo TM, Rossi EA, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm 2014. [Epub ahead of print]
76. Available from: http://www.meditope.com/aboutsnap.html [Accessed 17 January 2015]
77. Roberts SA, Andrews PA, Blanset D, et al. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. Regul Toxicol Pharmacol 2013;67:382-91
78. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other mmacromolecules in tumors. Cancer Res 1990;50:814s-9s
79. de Goeij BE, Peipp M, de Haij S, et al. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rationalantibody-drug conjugate design. MAbs 2014;6:392-402
80. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single mdomains. Nat Biotechnol 2005;23:1126-36
81. Spadiut O, Capone S, Krainer F, et al. Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol 2014;32:54-60
82. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5
83. Cao Y, Marks JD, Huang Q, et al. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 2012;11:143-53
84. Rudnick SI, Lou J, Shaller CC, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011;71:2250-9
85. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a noveltumor-targeting agent. Cancer Res 2007;67:254-61
86. Orcutt KD, Rhoden JJ, Ruiz-Yi B, et al. Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol Cancer Ther 2012;11:1365-72
87. Zimmerman Z, Maniar T, Nagorsen D. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE® ) antibody construct blinatumomab as a potential therapy. Int Immunol 2015;27:31-7
88. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm42 5549.htm [Accessed 17 January 2015]
89. Chen X, Ding G, Gao Q, et al. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLoS One 2013;8:e63093
90. Wang X, Zhu J, Zhao P, et al. In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells. Cancer Biol Ther 2007;6:980-7
91. Badescu G, Bryant P, Bird M, et al. Bridging disulphides for stable and defined antibody drug conjuates. Bioconj. Chem 2014;25:1124-36
92. Lillo AM, Sun C, Gao C, et al. A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalizationand delivery of antitumor agents. Chem Biol 2004;11:897-906
93. Ai J, Advani A. Current status of antibody therapy in ALL. Br J Haematol 2014. [Epub ahead of print]
94. Pye H, Stamati I, Yahioglu G, et al. Antibody directed phototherapy. Antibodies 2013;2:270-305
95. Bhatti M, Yahioglu G, Milgrom LR, et al. Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int J Cancer 2008;122:1155-63
96. Palumbo A, Hauler F, Dziunycz P, et al. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer 2011;104:1106-15
97. Kim KM, McDonagh CF, Westendorf L, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 2008;7:2486-97
98. Danielli R, Patuzzo R, Ruffini PA, et al. Armed antibodies for cancer treatment: a promising tool in a changing era. Cancer Immunol Immunother 2015;64:113-21
99. Bernardes GJ, Casi G, Trüssel S, et al. Traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl 2012;51:941-4
100. Perrino E, Steiner M, Krall N, et al. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res 2014;74:2569-78
101. Casi G, Huguenin-Dezot N, Zuberbühler K, et al. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J Am Chem Soc 2012;134:5887-92
102. Steiner M, Hartmann I, Perrino E, et al. Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature. Chem Sci 2013;4:297-302
103. List T, Casi G, Neri D. A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity. Mol Cancer Ther 2014;13:2641-52
104. Press release. Available from: http://www.marketwired.com/press-release/ablynx-spirogen-enter-into-research-collaboration-evaluate-potential-novel-toxin-nanobody-euronext-brussels-ablx-1760504.htm [Accessed 17 January 2015]
105. Deonarain MP. Antikor Biopharma presentation. World ADC Summit; San Diego: 2014
106. Reichert JM, Beck A, Lugovskoy AA, et al. 9th annual European Antibody Congress, November 11-13, 2013, Geneva Switzerland. MAbs 2014;6:309-26
107. Ying T, Gong R, Ju TW, et al. Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim Biophys Acta 2014;1844:1977-82
108. Wurch T, Pierre A & Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. TIBTECH 2012;30:575-82
109. Simon M, Fret R, Zangemeister-Wittke U, et al. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. Bioconj Chem 2013;24:1955-66
110. Balan S, Choi JW, Godvin A, et al. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconj. Chem 2007;18(1):61-76
111. Schumacher FF, Nunes JP, Maruani A, et al. Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging. Org Biomol Chem 2014;12:7261-9
112. Igenica patent. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use. WO197854; 2014
113. Tumey NL, Charati M, He T, et al. Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure and efficacy. Bioconj. Chem 2014;25(10):1871-80
114. Lyon RP, Setter JR, Bovee TD, et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat Biotechnol 2014;32:1059-62
115. Patterson JT, Asano S, Li X, et al. Improving the serum stability of site-specific antibody conjugates with sulfone linkers. Bioconj. Chem 2014;25:1402-7
116. Cal PM, Bernardes GJ, Gois PM. Cysteine-selective reactions for antibody conjugation. Angew Chem Int Ed Engl 2014;53:10585-7
117. Evans HL, Nguyen QD, Carroll LS, et al. A bioorthogonal (68)Ga-labelling strategy for rapid in vivo imaging. Chem Commun (Camb) 2014;50:9557-60
118. Diessner J, Bruttel V, Stein RG, et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Differ 2014;5:e1149
119. Regina A, Demeule M, Tripathy S, et al. NG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol Cancer Ther 2015;14:129-40
120. Xu K, Liu L, Dere R. Characterization of the drug to antibody ratio distribution for antibody drug conjugates in plasma/serum. Bioanalysis 2013;5:1057-71
121. Kaur S. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 2013;5:201-26